Zimmer Biomet HoldingsFRA:ZIM +1.29%76 FCF Margin % is 13.61% as of Mar. 2026, which is 22% below its 10-year median of 17.54. GuruFocus rates FRA:ZIM with a GF Score™ of 76/100 and a GF Value™ of €106.93 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks better than 85.77% on this metric.
The historical rank and industry rank for Zimmer Biomet Holdings's FCF Margin % or its related term are showing as below:
FRA:ZIM'
s FCF Margin % Range Over the Past 10 Years
Min: 14.8 Med: 17.54 Max: 19.98
Current: 16.26
During the past 13 years, the highest FCF Margin % of Zimmer Biomet Holdings was 19.98%. The lowest was 14.80%. And the median was 17.54%.
FRA:ZIM's FCF Margin % is ranked better than 85.77% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs FRA:ZIM: 16.26
Zimmer Biomet Holdings FCF Margin % Related Terms
Zimmer Biomet Holdings FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ZIM vs PEN, GMED, STE: FCF Margin % Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zimmer Biomet Holdings (FRA:ZIM) has a FCF Margin % of 13.61% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zimmer Biomet Holdings and its competitors. This is 22% below median its historical median of 17.54. Over the past decade, Zimmer Biomet Holdings' FCF Margin % has ranged from 14.80 to 19.98. According to the industry distribution chart, Zimmer Biomet Holdings ranks #116 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 14.2%.
Is Zimmer Biomet Holdings' FCF Margin % too high?
Zimmer Biomet Holdings' current FCF Margin % of 13.61% is 22% below median its 10-year median of 17.54. Over the past 10 years, this metric has ranged from a low of 14.80 to a high of 19.98. Based on the distribution chart, Zimmer Biomet Holdings ranks #116 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Zimmer Biomet Holdings has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' FCF Margin % compare to PEN and GMED?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #116 out of 815 companies for FCF Margin %. This places Zimmer Biomet Holdings in the top 14% of its industry — outperforming the majority of peers. Historically, Zimmer Biomet Holdings' own FCF Margin % has ranged from 14.80 to 19.98 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zimmer Biomet Holdings and its competitors. Zimmer Biomet Holdings's current FCF Margin % is 13.61%, which is 22% below median its own 10-year median of 17.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (FRA:ZIM) is currently considered Significantly Undervalued. The stock's GF Value™ is €106.93, compared to a current price of €76.80 — trading 28.2% below its estimated fair value. The current FCF Margin % is 13.61%, which is 22% below median its 10-year median of 17.54. Zimmer Biomet Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Zimmer Biomet Holdings (FRA:ZIM), the current FCF Margin % is 13.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (FRA:ZIM) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of €76.80 is trading 28.2% below its estimated GF Value™ of €106.93.
GuruFocus considers Zimmer Biomet Holdings to be Significantly Undervalued.
Key valuation signals for FRA:ZIM:
FCF Margin %: 13.61% (22% below median its 10-year median of 17.54)
GF Value™: €106.93 vs. price of €76.80 (28.2% below fair value)
No single metric tells the full story. See the FRA:ZIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
76GF Score
Get the complete analysis for FRA:ZIM
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZIM has been successfully added to your 
